Volume 28, Number 5—May 2022
Research
Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel
Aharona Glatman-Freedman
, Michal Bromberg, Yael Hershkovitz, Hanna Sefty, Zalman Kaufman, Rita Dichtiar, and Lital Keinan-Boker
, Michal Bromberg, Yael Hershkovitz, Hanna Sefty, Zalman Kaufman, Rita Dichtiar, and Lital Keinan-Boker
Table 2
Rate reduction of severe or critical disease among SARS-CoV-2–positive persons who received the BNT162b2 COVID-19 vaccine booster dose, Israel*
| Age group, y | Time of first positive SARS-CoV-2 PCR test after index date, wk |
Unvaccinated SARS-CoV-2–positive persons |
Vaccinated SARS-CoV-2–positive persons |
Adjusted 1 – IRR, % (95% CI)† | |||
|---|---|---|---|---|---|---|---|
| Severe or critical disease | Total | Severe or critical disease | Total | ||||
| 16–59 | 2 | 422 | 22,545 | 2 | 1,343 | 92.0 (70.0–97.9) | |
| 3 | 358 | 18,232 | 0 | 455 | 100.0 | ||
| 4 | 262 | 12,962 | 0 | 293 | 100.0 | ||
| 5 | 170 | 8,555 | 0 | 210 | 100.0 | ||
| 6 | 113 | 5,531 | 0 | 138 | 100.0 | ||
| 7 | 63 | 3,573 | 0 | 131 | 100.0 | ||
| 8 | 40 | 2,626 | 0 | 83 | 100.0 | ||
| 9 | 32 | 2,013 | 0 | 54 | 100.0 | ||
| 10 | 27 | 1,714 | 0 | 57 | 100.0 | ||
| 11 | 29 | 1,401 | 0 | 66 | 100.0 | ||
| 12 | 24 | 1,385 | 0 | 90 | 100.0 | ||
| 13 | 25 | 1,442 | 0 | 118 | 100.0 | ||
| 14 | 21 | 1,569 | 0 | 154 | 100.0 | ||
| 15 | 30 | 2,145 | 0 | 351 | 100.0 | ||
| 16 | 30 | 4,088 | 0 | 884 | 100.0 | ||
| 2–16 combined |
727 |
41,135 |
2 |
4,427 |
97.3 (89.7–99.3) |
||
| >60 | 2 | 450 | 1,985 | 56 | 1,314 | 81.9 (75.4–86.7) | |
| 3 | 470 | 2,200 | 27 | 464 | 73.5 (61.0–82.0) | ||
| 4 | 464 | 2,160 | 18 | 375 | 77.8 (63.1–86.8) | ||
| 5 | 469 | 2,164 | 15 | 319 | 78.9 (66.8–86.6) | ||
| 6 | 447 | 2,033 | 9 | 296 | 86.6 (74.2–93.0) | ||
| 7 | 390 | 1,724 | 12 | 271 | 81.4 (63.1–90.6) | ||
| 8 | 299 | 1,276 | 13 | 221 | 75.6 (54.1–87.0) | ||
| 9 | 207 | 869 | 2 | 147 | 94.6 (85.3–98.0) | ||
| 10 | 128 | 577 | 9 | 86 | 58.6 (11.1–80.7) | ||
| 11 | 78 | 376 | 2 | 63 | 86.2 (39.1–96.9) | ||
| 12 | 52 | 258 | 3 | 44 | 69.0 (−15.3 to 91.7) | ||
| 13 | 40 | 208 | 1 | 52 | 91.0 (63.8–97.8) | ||
| 14 | 42 | 183 | 2 | 49 | 84.0 (44.8–95.3) | ||
| 15 | 45 | 170 | 3 | 47 | 78.5 (49.3–90.8) | ||
| 16 | 37 | 162 | 3 | 44 | 70.3 (30.0–87.4) | ||
| 17 | 32 | 151 | 1 | 56 | 91.7 (43.4–98.8) | ||
| 18 | 28 | 147 | 0 | 69 | 100.0 | ||
| 19 | 33 | 184 | 4 | 125 | 83.6 (47.0–94.9) | ||
| 20 | 42 | 305 | 7 | 432 | 89.0 (75.8–95.0) | ||
| 2–20 combined | 1,465 | 6,673 | 187 | 4,474 | 81.6 (78.3–84.3) | ||
*COVID-19, coronavirus disease; IRR, incidence rate ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. †Adjusted for sex and epidemiologic week.
Page created: March 18, 2022
Page updated: April 19, 2022
Page reviewed: April 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.